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Abstract
Introduction Primary breast cancer involving four or more
axillary lymph nodes carries a poor prognosis. We hypothesized
that use of an immunohistochemical biomarker scoring system
could allow for identification of variable risk subgroups.
Methods Patients with four or more positive axillary nodes were
identified from a clinically annotated tissue microarray of
formalin-fixed paraffin-embedded primary breast cancers and
randomized into a 'test set' and a 'validation set'. A prospectively
defined prognostic scoring model was developed in the test set
and was further assessed in the validation set combining
expression for eight biomarkers by immunohistochemistry,
including estrogen receptor, human epidermal growth factor
receptors 1 and 2, carbonic anhydrase IX, cytokeratin 5/6,
progesterone receptor, p53 and Ki-67. Survival outcomes were
analyzed by the Kaplan–Meier method, log rank tests and Cox
proportional-hazards models.
Results A total of 313 eligible patients were identified in the test
set for whom 10-year relapse-free survival was 38.3% (SEM
2.9%), with complete immunohistochemical data available for
227. Tumor size, percentage of positive axillary nodes and
expression status for the progesterone receptor, Ki-67 and
carbonic anhydrase IX demonstrated independent prognostic
significance with respect to relapse-free survival. Our combined
biomarker scoring system defined three subgroups in the test
set with mean 10-year relapse-free survivals of 75.4% (SEM
7.0%), 35.3% (SEM 4.1%) and 19.3% (SEM 7.0%). In the
validation set, differences in relapse-free survival for these
subgroups remained statistically significant but less marked.
Conclusion Biomarkers assessed here carry independent
prognostic value for breast cancer with four or more positive
axillary nodes and identified clinically relevant prognostic
subgroups. This approach requires refinement and validation of
methodology.
Introduction
Prognostic assessment for early breast cancer in the clinic is
currently made from clinical and pathological parameters,
which at present include three biomarkers: estrogen receptor
(ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2) [1-3]. Of these conventional
prognostic factors, nodal status is consistently held to be the
most important parameter for determining prognosis [3-5].
The widely referenced St Gallen consensus guidelines, for pri-
mary therapy of early breast cancer, define patients with four
or more positive axillary nodes as 'high risk' irrespective of the
status of any other prognostic factor [5]. From the perspective
of recommendations for the use of adjuvant chemotherapy, the
presence of four or more positive axillary lymph nodes defines
CA IX = carbonic anhydrase IX; CI = confidence interval; CK5/6 = cytokeratin 5/6; EGFR = human epidermal growth factor receptor 1; ER = estrogen 
receptor; FISH = fluorescence in situ hybridization; HER2 = human epidermal growth factor receptor 2; OS = overall survival; PR = progesterone 
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all such patients into a group offered treatment regardless of
other conventional parameters aside from performance status
and age [5,6].
It has become clear that breast cancer is in fact a collection of
heterogeneous disease processes, with variable biological
behavior and outcome, that current models for prognostication
do not completely capture [2,7-12]. Protein or mRNA expres-
sion profiling has been shown to permit the molecular classifi-
cation of breast cancers via a range of techniques including
cDNA microarray, quantitative RT-PCR and tissue microarray
(TMA) into consistently observable groupings [7-10,12-19].
Each of these approaches provides prognostic information
through a molecular subtype classification of breast cancer,
but there is less evidence as to how these approaches com-
pare or add to the use of conventional prognostic factors [7-
10,14,17,18]. The potential to use such methodologies, in the
setting of axillary lymph node negative breast cancer, to inform
the decisions regarding chemotherapy is currently being
tested in prospective randomized trials [1,17-21].
We hypothesized that TMA profiling of a panel of biomarkers,
either proven or potentially relevant for prognostic and/or pre-
dictive assessment of breast cancer, might permit the detec-
tion of clinically relevant prognostic groups from those with
four or more positive axillary lymph nodes above that attainable
from conventional factors alone. Such information might be
helpful in providing treatment recommendations and progno-
sis but might also be helpful in the design and stratification of
patients on clinical trials.
Materials and methods
Study population
The study population was derived from a TMA constructed
from archival formalin-fixed paraffin-embedded specimens of
4,444 patients from the Canadian province of British Colum-
bia. All patients had been diagnosed with invasive breast can-
cer without metastatic disease between 1986 and 1992, and
represented 34% of patients diagnosed with breast cancer
during this period [22]. Clinical and pathological information
was collected prospectively through the Breast Cancer Out-
comes Unit Database of the British Columbia Cancer Agency.
Patients were randomly allocated into two groups of 2,222
after stratification for treatment. Inclusion criteria for this study
were: female sex, known cause of death, new breast cancer
diagnosis at the time of referral to the British Columbia Cancer
Agency, and a known number of positive axillary lymph nodes.
From this set, those patients with four or more positive axillary
nodes formed the final cohorts. The 'test set' was used to
define prognostic subgroups based on patterns of immunohis-
tochemical biomarker expression. The prognostic value of the
biomarker-derived subgroups was then further evaluated in
the 'validation set'. The study was approved by the Clinical
Research Ethics Board of the University of British Columbia.
Tissue microarray, immunohistochemistry and 
biomarker scoring
TMAs were constructed as described previously, requiring 17
TMA blocks [22]. TMA slides were stained for eight biomark-
ers by immunohistochemistry. ER (SP1, dilution 1:250), HER2
(SP3, dilution 1:100) and Ki-67 (SP6, dilution 1:200) were
from Lab Vision (Fremont, CA, USA). Human epidermal
growth factor receptor 1 (EGFR; PharmDx Kit, undiluted) and
p53 (DO-7, dilution 1:400) were from Dako Corporation
(Carpinteria, CA, USA). PR (1E2, undiluted) was from Ventana
Medical Systems (Tucson, AZ, USA). Cytokeratin 5/6 (CK5/6;
D5/16B4, dilution 1:100) was from Zymed Laboratories (San
Francisco, CA, USA). Carbonic anhydrase IX (CA IX; M75,
dilution 1:50) was a gift from Dr Stephen Chia (British Colum-
bia Cancer Agency, BC, Canada) [23]. Biomarkers were cho-
sen for known prognostic, and in some cases predictive, effect
and relevance to biologic classification of subtypes. There
were no assumptions about which would be of value for the
detection of patients with good versus poor prognosis in the
study cohort. Cut points to dichotomize outcome were defined
prospectively as follows. ER, <1% versus ≥1% nuclei stained;
PR, <1% versus ≥1% nuclei stained; EGFR, negative versus
any staining; Ki-67, <10% versus ≥10% positive nuclei; p53,
≤10% versus >10% positive nuclei; CA IX, negative versus
tumor and/or stroma positive; CK5/6, negative versus any
staining. For HER2, TMA slides were scored by using the
immunohistochemical HercepTest (Dako Corporation) scor-
ing system. Cases with a HER2 HercepTest score of 3 were
scored as positive, and those of 0 or 1 were scored as nega-
tive. Those cases with HER2 HercepTest score of 2 were re-
evaluated by using fluorescence in situ hybridization (FISH)
assays, and only those cases with a HER2 FISH amplification
ratio of at least 2.0 were scored as HER2 positive.
The full set of eight biomarkers were not available for all
patients as a result of tissue cores falling off slides during
processing, insufficient or absent tumor tissue within cores, or
artefactual distortion of the tissue making interpretation impos-
sible. Stained TMA slides were digitally scanned and linked to
a relational database [22,24]. For each biomarker, images
were scored visually by two pathologists, blinded to clinical
outcome. An internet website was then constructed from this
database by using a WebSlide-Viewer Java applet provided by
the manufacturer to view the microarray images and to permit
an image-zooming functionality. This website is publicly acces-
sible [25].
Statistical analysis and result validation
Statistical analysis was performed with SPSS software, ver-
sion 13.0 (SPSS Inc, Chicago, IL, USA). Univariate analysis of
relapse-free and overall survival was performed with the Kap-
lan–Meier method, with survival differences analyzed by log
rank tests. Cox proportional-hazards models were used to
determine hazard ratios in univariate and multivariate analyses.
P < 0.05 was considered statistically significant. The primaryAvailable online http://breast-cancer-research.com/content/10/1/R6
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outcome measure for this study was of relapse-free survival
(RFS); the secondary outcome measure was overall survival
(OS). RFS was defined as the time from the date of diagnosis
to either the first local, regional or distant recurrence or death
from breast cancer before a recorded relapse. OS was calcu-
lated from the time of diagnosis to death from any cause. We
used a split-sample validation technique for statistical analysis,
as described previously [22]. In brief, a large data collection (n
= 4,444) was randomly split into a 'test' set and a 'validation'
set, each containing 2,222 observations. After exploratory
analyses with the test set, selected final analyses were
repeated with the validation set. Analyses with the validation
set were undertaken by a different investigator from those
using the test set.
Determination of mean predicted relapse-free survival 
outcomes
Ten-year outcomes for RFS were determined by Kaplan–
Meier analysis for the test set for the overall eligible cohort and
prognostic subgroups defined in this study. These were com-
pared with the means of the predicted RFS values for each
patient with respect to these same subgroups provided by the
online breast cancer prognostic tool Adjuvant! (version 8.0,
accessed 29 December 2006) [26-28]. In determining pre-
dicted outcomes by Adjuvant! for each patient, a default option
of 'average for age' was selected for the 'comorbidity' data
entry point. Data for age, pathological ER status, tumor grade,
tumor size, number of positive axillary nodes (four to nine ver-
sus ten or more), and type of hormonal therapy and chemo-
therapy used were inputted from abstracted clinical and
pathological details.
Results
In the test set, the number of positive axillary nodes was known
for 2,115 patients. Of these, 325 had four or more positive
axillary lymph nodes, from which 313 met the remaining eligi-
bility criteria for inclusion. Scoring was possible for all eight of
the biomarkers assessed for 227 of these 313 patients. Base-
line clinical, pathological and treatment details are shown in
Table 1 for the 313-patient overall test set cohort and for the
227-patient subgroup with complete biomarker scores. The
227-patient subgroup did not differ from the 313-patient over-
all group with respect to median RFS (5.2 years (95% confi-
dence interval (CI) 3.6 to 6.9) and 5.2 years (3.9 to 6.5),
respectively) or overall survival (6.6 years (5.2 to 8.0) and 6.7
years (5.7 to 7.8), respectively).
Univariate analysis of conventional prognostic markers was
performed with respect to RFS in the test set (Table 2).
Increasing tumor grade (grade 3 versus 1 or 2), increasing
tumor size, negative baseline pathological ER status, presence
of lymphovascular invasion and increasing percentage of pos-
itive axillary nodes were predictive of inferior outcome with
respect to RFS. In multivariate Cox regression analysis, base-
line pathological ER status (P = 0.0005) and tumor size (P =
0.03) retained prognostic significance (Table 3).
The prognostic value of eight biomarkers determined by immu-
nohistochemistry with TMA was assessed. In univariate analy-
sis within the test set (Table 4), increased expression of
EGFR, Ki-67, p53 and CA IX, and lower expression of ER and
PR, indicated poorer prognosis with respect to RFS.
Increased expression of HER2 and CK5/6 did not significantly
predict outcomes. In multivariate Cox regression analysis
inclusive of all eight biomarkers, PR (P = 0.006), Ki-67 (P =
0.001) and CA IX (P = 0.03) retained independent prognostic
significance in the test set (Table 5).
Univariate analysis of RFS outcomes was repeated for the
same eight biomarkers within the validation set (Table 4). In
this cohort, 289 had four or more positive axillary lymph nodes
and met the eligibility criteria, with 219 having data for all eight
biomarkers for analysis. Biomarkers reaching statistical signif-
icance with respect to RFS in the validation set were ER, PR,
HER2 EGFR, CA IX and CK5/6.
To investigate the ability to stratify patients into prognostic
groups by using these biomarkers, a scoring system based on
immunohistochemical scores was created to define prognos-
tic subgroups within the test set. Among the 227 patients with
scores for all eight biomarkers in the test set, we scored the
dichotomized outcome for each marker as 0 for good progno-
sis and 1 for poor prognosis with respect to univariate analysis
of RFS outcomes (that is, 1 each if ER negative or PR nega-
tive, and 1 each if positive with respect to the other six biomar-
kers). Each patient was therefore assigned a score from 0 to
8. Patients were then banded by this score into three groups
based on scores of 0, 1 to 4, or 5 to 8. Banding was performed
without assumption regarding the relative importance of each
marker or weighting to any one in particular and was defined
prospectively. In considering the use of adjuvant chemother-
apy for these three scoring groups, an imbalance was seen
with use in 35.1%, 52.6% and 73.0% of the 0, 1 to 4, and 5
to 8 scoring groups, respectively. RFS outcomes for the three
banded groups were markedly different within the test set (Fig-
ure 1 and Table 6). The subgroup scoring 0 for all eight
biomarkers (38 patients, 16.7%) had 10-year RFS of 75.4%
(SEM 7.1%) with a median not yet reached at a median follow-
up of 11.7 years. By comparison, the groups scoring 1 to 4
(154 patients, 67.8%) and 5 to 8 (35 patients, 15.4%) had 10-
year RFS rates of 35.3% (SEM 4.1%) and 19.3% (SEM
7.0%), and median RFS of 4.8 years (95% CI 3.6 to 6.1) and
1.6 years (95% CI 0.8 to 2.3), respectively. Similar differences
in median and 10-year outcomes were also seen with respect
to overall survival (Figure 1 and Table 6), which again deter-
mined good outcome for the group scoring 0 for all eight
markers.Breast Cancer Research    Vol 10 No 1    Crabb et al.
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Table 1
Frequencies of conventional prognostic factors and adjuvant treatments in the test set
Factor Division Whole set (313 patients) Subset (227 patients)
n Percentage n Percentage
Age ≤40 34 10.9 25 11.0
>40 279 89.1 202 89.0
Menopausal status Pre 104 33.2 76 33.5
Post 203 64.9 147 64.8
Unknown 6 1.9 4 1.8
Tumor grade 1 5 1.6 4 1.8
2 101 32.3 71 31.3
3 191 61.0 144 63.4
Unknown 16 5.1 8 3.5
Tumor size, cm 0–2 100 31.9 71 31.3
> 2–5 173 55.3 131 57.7
> 5 35 11.2 22 9.7
Unknown 5 1.6 3 1.3
Pathological ER status Negative 72 23.0 54 23.8
Positive 234 74.8 169 74.4
Unknown 7 2.2 4 1.8
Lymphovascular invasion Negative 49 15.7 33 14.5
Positive 244 78.0 184 81.1
Unknown 20 6.4 10 4.4
Percentage of positive nodes 0–50 121 38.7 89 39.2
>50–99.9 142 45.4 95 41.9
100 50 16.0 43 18.9
Number of positive nodes 4–9 235 75.1 175 77.1
≥10 78 24.9 52 22.9
Histology Ductal 279 89.1 210 92.5
Lobular 34 10.9 17 7.5
Adjuvant chemotherapy No 155 49.5 107 47.1
Yes 158 50.5 120 52.9
Adjuvant hormonal therapy No 104 33.2 78 34.4
Yes 209 66.8 149 65.6
Adjuvant radiotherapy No 70 22.4 50 22.0
Yes 243 77.6 177 78.0
Mastectomy No 2 0.6 1 0.4
Complete 217 69.3 154 67.8
Partial 94 30.0 72 31.7
Data are presented for the 313-patient test set cohort, and for the 227-patient subgroup in which expression data were available for each of the 
eight immunohistochemical biomarkers assessed. Percentages are rounded.Available online http://breast-cancer-research.com/content/10/1/R6
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The same analysis was repeated in the validation set with
respect to this scoring system. OS and RFS by Kaplan–Meier
analysis demonstrated statistically significant differences
between the prognostic subgroups; however, the difference in
survival outcomes was less marked between the prognostic
groups compared with the test set (Figure 1). Confidence
intervals overlapped for both RFS and OS for the groups scor-
ing 0 and 1 to 4 but were non-overlapping between the groups
scoring 1 to 4 and 5 to 8 (Table 6).
After this, we compared actual RFS outcome within the test
set of each banded group with the mean of the predictions for
10-year RFS outcomes determined by the online prognostic
tool Adjuvant! [27,28]. This program uses conventional prog-
nostic factors of age, comorbidity, ER status, grade, tumor size
and number of positive nodes and provides an estimated out-
come with respect to different options for adjuvant systemic
therapies. Consistent with previous validation of Adjuvant! in a
large population-based cohort [26], mean predicted values for
RFS at 10 years agreed closely with actual outcomes deter-
mined by Kaplan–Meier analysis in the overall 313-patient
cohort (Figure 2) and additionally for the 227-patient sub-
group with scores for all eight biomarkers (data not shown). In
contrast, for the good-prognosis subgroup scoring zero for all
eight biomarkers, the mean of predictions for percentage 10-
year RFS by Adjuvant! was 36.7%, but a better actual
outcome of 75.4% (SEM 7.1%) was in fact observed. Values
for the 5 to 8 biomarker score group were 33.4% and 19.3%
(SEM 7.0%), respectively, indicating an actual outcome that
was worse in this group than predicted by Adjuvant!. By
comparison, values for the intermediate group scoring 1 to 4
were similar at 34.4% and 35.3% (SEM 4.1), respectively.
Table 2
Univariate analysis of relapse-free survival for conventional prognostic factors in the test set cohort
Factor n/313 Divisions n Median RFS, 
years (95% CI)
HR (95% CI) P
Overall 313 5.2 (3.9–6.5)
Age 313 ≤40 34 2.9 (1.3–4.5) 1
>40 279 5.6 (4.2–7.0) 0.74 (0.48–1.13) 0.2
Menopausal 
status
307 Pre 104 3.7 (2.1–5.2) 1
Post 203 6.0 (3.9–8.2) 0.79 (0.59–1.05) 0.1
Tumor grade 297 1, 2 5, 101 9.5 (4.9–14.2) 1
3 191 4.0 (3.3–4.8) 1.24 (1.06–1.45) 0.007
Tumor size, cm 308 0 to 2 100 11.0 1
>2 to 5 173 4.5 (3.5–5.6) 1.67 (1.21–2.33) 0.002
>5 35 3.0 (0–6.2) 1.55 (0.95–2.54) 0.08
Pathological ER 
statusa
306 Negative 72 2.0 (0.9–3.0) 1
Positive 234 6.8 (4.0–9.5) 0.53 (0.38–0.72) 0.00007
Lymphovascular 
invasion
293 Negative 49 12.0 (5.3–18.8) 1
Positive 244 4.5 (3.5–5.4) 1.73 (1.13–2.66) 0.01
Percentage of 
positive nodes
313 0–50 121 9.2 (5.7–12.8) 1
>50–99 142 4.8 (3.5–6.2) 1.52 (1.11–2.09) 0.01
100% 50 3.1 (1.8–4.4) 1.96 (1.30–2.94) 0.001
Number of 
positive nodes
313 4–9 235 5.3 (3.9–6.7) 1
≥10 78 4.8 (2.1–7.6) 1.16 (0.85–1.60) 0.4
Histology 313 Ductal 279 5.1 (3.8–6.5) 1
Lobular 34 6.4 (2.7–10.1) 1.16 (0.76–1.77) 0.5
P, significance for the comparison of hazard ratios; ER, estrogen receptor; RFS, relapse-free survival; CI, confidence interval; HR, hazard ratio.
aPathological ER status at diagnosis.Breast Cancer Research    Vol 10 No 1    Crabb et al.
Page 6 of 11
(page number not for citation purposes)
Having seen a less impressive distinction between prognostic
groups with our biomarker scoring system in the validation set,
we performed exploratory multivariate analysis using the com-
bined test and validation sets inclusive of baseline prognostic
factors and each TMA biomarker. Similarly to the results in the
test set, tumor size, percentage of positive axillary nodes and
the TMA biomarkers PR, Ki-67 and CA IX each maintained
independent prognostic significance with respect to RFS
(Table 7).
Discussion
Early breast cancer involving four or more axillary nodes carries
a poor prognosis; however, a proportion of patients do well
and are cured of their disease. Ten-year RFS rates of 38%
seen in this study mirror those from historical series [4]. Man-
agement decisions might be improved if prognostic sub-
groups can be identified.
We first investigated current conventional prognostic factors
for breast cancer to assess their ability to determine prognosis
in such patients. Tumor size and percentage of positive axillary
nodes were the most important factors, with each retaining
prognostic significance in multivariate analysis, consistent with
previous data for each [4,29]. Both reflect overall tumor
burden at diagnosis, increasing risk of occult metastatic dis-
ease at diagnosis and issues of surgical resectability. Addi-
tionally, we addressed the utility of eight biomarkers to
determine prognosis in this group. Of these, PR, Ki-67 and CA
IX retained prognostic significance after multivariate analysis
that included conventional prognostic factors. The biological
relevance of each in determining prognosis must remain
somewhat speculative. PR might be important in prognostica-
tion in luminal-type subclasses, which remain an indistinct area
of breast cancer molecular subtype classification. PR expres-
sion may show independent prognostic value (in addition to
molecular markers for genomic grade) in ER-positive breast
cancers, and this seems to be mirrored in our study for heavily
node-positive disease [13]. Ki-67 is probably represented
here as a marker of tumor proliferation relating to intrinsic phe-
notypic aggressiveness, risk of occult metastatic disease and
as a predictive factor for responsiveness to systemic thera-
pies. Finally, the hypoxia-inducible gene CA IX is an estab-
lished and validated poor prognostic factor in breast cancer
[23,30]. Its precise function remains inadequately determined
and so the underlying biological explanation for its independ-
ent prognostic value in this cohort remains to be fully
explained.
Our attempt to develop a prospectively defined prognostic
scoring system, based on immunohistochemical biomarkers,
for this patient group resulted in marked separation in survival
outcomes within the test set cohort. In the validation set,
cohort distinction in outcomes with this scoring system,
although retaining statistical significance, indicated smaller
differences between subgroups. This approach would there-
fore seem to be an imperfect method of predicting differential
outcomes among those with four or more positive axillary
nodes, and the scoring method described here requires refine-
ment. Our results do, however, indicate that conventional
baseline prognostic factors can be usefully augmented by the
addition of information derived from molecular biomarkers in
patients with heavy axillary nodal involvement, who as a group
have received less attention in the age of molecular breast
cancer subtyping. Options for refinement of our approach
might include incorporation of other biomarkers that have
been shown to predict prognosis independently of conven-
tional prognostic factors for breast cancer, for example Bcl-2
[31]. Alternatives to immunohistochemistry for detection and
expression analysis of relevant prognostic genes may also be
appropriate; for example, analysis by array-comparative
genomic hybridization, cDNA microarray and RT-PCR
approaches have each been shown to permit prognostic clas-
sification [11,12,16-19,21,32-34]. The most appropriate
methodology for subsequent application in the clinic has yet to
be defined.
The finding in the test set that the Adjuvant! online prognostic
tool predicted accurately for the overall group but did not dis-
criminate those within different prognostic groups argues for
the validation of molecular markers that can enhance such a
mathematical model to individualize prognostic information fur-
ther and be more sensitive to the heterogeneity of the disease.
Such approaches are being prospectively tested in the axillary
node negative setting [1,17-21] and we believe they also hold
promise in those with heavy axillary nodal involvement.
Our internal validation approach represents one option for
exploratory testing and subsequent confirmation of experimen-
tal prognostic methodologies. It is widely accepted that valida-
Table 3
Multivariate analysis for relapse-free survival in the test set 
cohort of baseline prognostic factors
Factor Hazard ratio (95% 
CI)
P
Grade (3 versus 1 or 2) 1.20 (0.84–1.70) 0.3
Tumor size, cm 0.03
>2–5 versus 0–2 1.62 (1.12–2.33) 0.01
>5 versus 0–2 1.23 (0.71–2.12) 0.5
Pathological ER statusa 0.53 (0.37–0.76) 0.0005
Lymphovascular invasion 1.32 (0.84–2.09) 0.2
Percentage of positive nodes 0.09
>50–99 versus 0–50 1.22 (0.87–1.73) 0.3
100 versus 0–50 1.62 (1.05–2.50) 0.03
Multivariate Cox regression analysis was performed inclusive of 
those factors reaching statistical significance in univariate analysis. 
ER, estrogen receptor; CI, confidence interval.
aPathological ER status at diagnosis.Available online http://breast-cancer-research.com/content/10/1/R6
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tion in independent cohorts, from those in which a model is
originally derived, is a mandatory step in the development of
prognostic methods. However, no clear consensus exists on
the most robust internal method of undertaking this. Others
have advocated alternatives to our straightforward approach
of randomization to two cohorts, such as dividing data in a
non-random way (for example by time period of patient pres-
entation) or the use of bootstrapping or 'leave one out' cross-
validation approaches [35]. The gold standard remains exter-
nal validation by separate investigators, but this leaves the
issue of how best to first internally validate findings.
Table 4
Univariate analysis of relapse-free survival for immunohistochemical biomarkers in the test and validation sets
Set Biomarker +/- n/total n Median RFS, years (95% CI) HR (95% CI) P
Test ER - 308/313 100 2.9 (1.7–4.1) 1
+ 208 6.1 (4.1–8.1) 0.70 (0.52–0.93) 0.02
PR - 279/313 143 3.0 (2.1–3.8) 1
+ 136 8.2 (5.0–11.4) 0.58 (0.43–0.78) 0.0003
HER2 - 300/313 240 6.0 (4.4–7.6) 1
+ 60 3.6 (2.1–5.1) 1.33 (0.94–1.89) 0.1
EGFR - 271/313 239 6.0 (4.0–8.0) 1
+ 32 1.6 (0.9–2.3) 2.30 (1.49–3.56) 0.0002
Ki-67 - 308/313 140 11.0 (6.5–15.6) 1
+ 168 3.6 (2.8–4.4) 1.93 (1.44–2.60) 0.00001
p53 - 307/313 235 6.4 (4.3–8.6) 1
+ 72 2.6 (1.9–3.3) 1.59 (1.16–2.18) 0.004
CA IX - 281/313 234 5.7 (4.0–7.4) 1
+ 47 2.5 (1.4–3.6) 1.81 (1.26–2.62) 0.002
CK5/6 - 260/313 238 5.2 (3.8–6.6) 1
+ 22 2.5 (0.6–4.3) 1.60 (0.94–2.73) 0.08
Validation ER - 288/289 100 2.6 (1.5–3.8) 1
+ 188 7.2 (5.8–8.5) 0.68 (0.50–0.92) 0.01
PR - 268/289 143 3.8 (2.1–5.5) 1
+ 125 7.2 (6.1–8.3) 0.73 (0.54–1.00) 0.05
HER2 - 273/289 206 7.0 (5.8–8.2) 1
+ 67 2.4 (1.5–3.2) 1.55 (1.11–2.18) 0.01
EGFR - 257/289 219 6.6 (4.9–8.3) 1
+ 38 2.1 (1.3–2.8) 1.81 (1.21–2.70) 0.004
Ki-67 - 289/289 134 7.2 (5.6–8.8) 1
+ 155 4.8 (3.0–6.6) 1.27 (0.94–1.70) 0.12
p53 - 286/289 223 6.7 (5.1–8.2) 1
+ 63 2.7 (0.5–4.9) 1.40 (0.99–1.97) 0.06
CA IX - 271/289 227 7.1 (5.4–8.6) 1
+ 44 2.3 (1.3–3.2) 1.79 (1.23–2.61) 0.002
CK5/6 - 252/289 237 6.0 (4.3–7.6) 1
+ 15 2.4 (1.7–3.1) 1.81 (1.00–3.27) 0.05
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; EGFR, human epidermal growth factor 
receptor 1; CA IX, carbonic anhydrase IX; CK5/6, cytokeratin 5/6; RFS, relapse-free survival; CI, confidence interval; HR, hazard ratio; P, 
significance for comparison of hazard ratio.Breast Cancer Research    Vol 10 No 1    Crabb et al.
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With respect to potential limitations of our study, our TMA
cohort includes patients presenting between 1986 and 1992,
who were treated in accordance with therapeutic strategies
that have since evolved. Overall, the figure of only 50.5%
receiving chemotherapy in the test set is significantly lower
than would be expected for this patient group in the modern
era. Furthermore, no patients received certain treatments
options that are now standard, such as trastuzumab or tax-
anes. However, we believe our conclusions remain valid, for
three reasons. First, we have found a difference in the use of
chemotherapy between the three prognostic groups created
by the novel scoring system developed in our study (35.1%,
52.6% and 73.0% of the 0, 1 to 4 and 5 to 8 scoring groups,
respectively). If one assumes that the chemotherapy will have
improved outcome in the three respective groups, then the
imbalance would in fact have biased against seeing a differ-
ence in the three prognostic groups we had created. The use
of RFS as an outcome might be affected by treatment imbal-
ance. However, we have also provided data for overall survival
that essentially showed similar, if less marked, findings for out-
comes with respect to the three prognostic divisions created.
Second, since the mid 1970s, the British Columbia Cancer
Agency has periodically circulated updated consensus provin-
cial practice guidelines to all physicians in the province. Pub-
lished data from the time span of this study confirm that the
degree of compliance with provincial practice guideline rec-
ommendations for radiotherapy, chemotherapy and tamoxifen
was high [36]. We believe that the same excellence for achiev-
ing management standards in the heavily node-positive dis-
ease cohort considered here can be assumed. Third, this large
cohort, derived from a TMA including more than 4,400
patients and from within a single healthcare setting, comprises
Figure 1
Relapse-free and overall survival by banded biomarker score in the test and validation sets Relapse-free and overall survival by banded biomarker score in the test and validation sets. For each patient, scores for eight immunohistochemical 
biomarkers assessed were determined; each biomarker was scored as 1 if predicting poor prognosis in univariate analysis for that patient. Patients 
were then banded by scores of 0, 1 to 4, and 5 to 8. P values were obtained by log rank test.
Table 5
Multivariate analysis of relapse-free survival in the test set for 
all eight tissue microarray biomarkers
Biomarker HR (95% CI) P
ER 0.87 (0.55–1.38) 0.5
PR 0.58 (0.39–0.86) 0.006
HER2 0.93 (0.61–1.42) 0.7
EGFR 1.20 (0.63–2.29) 0.6
Ki-67 1.99 (1.32–3.00) 0.001
p53 0.88 (0.58–1.35) 0.6
CA IX 1.67 (1.06–2.64) 0.03
CK5/6 0.81 (0.43–1.54) 0.5
ER, estrogen receptor; PR, progesterone receptor; HER2, human 
epidermal growth factor receptor 2; EGFR, human epidermal growth 
factor receptor 1; CA IX, carbonic anhydrase IX; CK5/6, cytokeratin 
5/6; HR, hazard ratio for positive expression status for that marker; 
CI, confidence interval.Available online http://breast-cancer-research.com/content/10/1/R6
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patients presenting during the period 1986 to 1992 and is
'population based' by nature, which is a strength of the data
set. Chemotherapy should therefore be expected to be a less
commonly used modality. A further question with regard to
TMA-based biomarker studies is the quality of the pathological
samples available and the concordance between the eligible
patient cohort and those with scorable results for marker(s) of
interest. In our study all eight biomarkers were scored in 227
of 313 patients in the test set cohort. Baseline pathological
characteristics and survival outcomes were not significantly
different in this subgroup from those in the overall group. Thus,
our biomarker data are likely to be representative of the group
as a whole.
Conclusion
This study demonstrates that conventional prognostic factors
of tumor size and the percentage of positive axillary nodes,
together with biomarkers of PR, Ki-67 and CA IX, are inde-
pendent prognostic factors in breast cancer patients with four
or more positive axillary lymph nodes. Our prognostic scoring
system, based on the expression of eight biomarkers, identi-
fied markedly different survival outcomes in the test set, with
less marked but statistically significant differences in the vali-
dation set. This study highlights the importance of validation of
initial findings. Further investigation is warranted to determine
how prognostic stratification can best be evolved to incorpo-
rate biomarkers to permit the development of more tailored
therapeutic decision making for this patient group.
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0 38/227 NR 75.4 (7.1) 40/219 9.7 (5.5–14.0) 47.8 (8.4)
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Comparison of mean predictions for relapse-free survival by Adjuvant!  with actual outcomes Comparison of mean predictions for relapse-free survival by Adjuvant! 
with actual outcomes. Predicted outcome for percentage relapse-free 
survival at 10 years for each patient, based on their baseline clinical 
and pathological factors, was determined with the online prognostic 
tool Adjuvant!. The means of these predicted outcomes (black bars) are 
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